The S&P 600 SmallCap index offers quality small-cap exposure, emphasizing companies with positive earnings and robust ...

The SOXX ETF surged 41% in 2025 on AI chip demand. Explore catalysts, valuation risks, and why it’s rated BUY—read now to ...

While Aether Holdings (ATHR) is still in an investment phase, its balance sheet provides significant flexibility. The company carries no debt and reports a current ratio above 11, reflecting strong ...

Past returns often dominate mutual fund discussions, but they don’t tell the full story. Understanding risk, consistency and ...

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

Learn more about whether nLIGHT, Inc. or Mirion Technologies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The approval makes AQVESME the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, a rare blood disorder. The drug is expected ...

Discover essential metrics like alpha, beta, and Sharpe ratio for evaluating mutual fund risk-return tradeoffs. Learn how to assess potential returns and risks effectively.

Explore the Security Market Line in CAPM to assess stock value and risk, aiding investment decisions and enhancing portfolio management.